financetom
Business
financetom
/
Business
/
Salesforce Launches Agentforce, Redefining AI In Business With Autonomous Solutions
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Salesforce Launches Agentforce, Redefining AI In Business With Autonomous Solutions
Nov 3, 2024 2:09 PM

Salesforce, Inc. ( CRM ) shares are trading higher on Tuesday. The company introduced Agentforce, which is a new feature that enables companies to develop AI agents capable of autonomously performing tasks across various business functions.

Agentforce uses advanced reasoning to make decisions and execute actions, such as resolving customer inquiries and optimizing marketing campaigns. These agents operate independently, triggered by data changes, business rules, or API signals.

Agentforce includes customizable out-of-the-box agents that are easily deployed using low-code or no-code tools, operating continuously across all channels.

The first available agent, the Agentforce Service Agent, outperforms traditional chatbots by handling a broad range of tasks, from simple inquiries to complex issues, with pre-built topics and actions for customer support.

Users can tailor these agents for different industries, such as retail for order management or financial services for billing and payment support.

The Agentforce layer is seamlessly integrated into the Salesforce Platform, leveraging data, AI, and Salesforce’s Customer 360 ecosystem, all built on a reliable foundation.

This integration enhances the capabilities of agents, allowing for unlimited scalability, proactive actions across various roles and channels, and contextual awareness of every customer interaction.

Read: ‘Copilot’s A Flop Because Microsoft Lacks The Data,’ Salesforce ( CRM ) CEO Slams Rebranding Of AI Tool To ‘Agents:’ ‘That’s Panic Mode’

Investors can gain exposure to the stock via iShares Expanded Tech-Software Sector ETF and First Trust DJ Internet Index Fund .

Price Action: CRM shares are up 1.87% at $299.26 at the last check Tuesday.

Image via Shutterstock

Read Next:

Marc Benioff Warns Microsoft’s Copilot ‘Spills Corporate Data,’ Emphasizes Security Gaps Ahead Of Salesforce Agentforce Launch

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Ansys to Sell PowerArtist Business to Keysight
Ansys to Sell PowerArtist Business to Keysight
Jan 6, 2025
04:58 PM EST, 01/06/2025 (MT Newswires) -- Ansys ( ANSS ) and Synopsys ( SNPS ) said Monday that Ansys ( ANSS ) has agreed to sell its PowerArtist business to Keysight Technologies ( KEYS ) . The terms of the deal weren't provided. The deal is subject to review by regulators and the closing of Synopsys' ( SNPS )...
Olema Pharmaceuticals Files Shelf for 2 Equity Offerings
Olema Pharmaceuticals Files Shelf for 2 Equity Offerings
Jan 6, 2025
04:59 PM EST, 01/06/2025 (MT Newswires) -- Olema Pharmaceuticals ( OLMA ) late Monday disclosed plans for two prospective securities offerings, including up to $200 million of its common or preferred stock, warrants to buy shares or debt securities. The company, which is developing cancer therapies for women, also plans potential sale of up to $150 million of its common...
BRIEF-Beta Bionics Files For IPO
BRIEF-Beta Bionics Files For IPO
Jan 6, 2025
Jan 6 (Reuters) - * BETA BIONICS INC - FILES FOR IPO * BETA BIONICS INC - APPLIES TO LIST ON NASDAQ UNDER SYMBOL 'BBNX' * BETA BIONICS INC: SAYS BOFA SECURITIES, PIPER SANDLER, LEERINK PARTNERS, STIFEL, LAKE STREET ARE THE UNDERWRITERS * BETA BIONICS INC SAYS ENTITIES AFFILIATED WITH EVENTIDE ASSET MANAGEMENT BENEFICIALLY OWNED 16.7% OF COMMON SHARES PRIOR...
Denali Therapeutics' ALS drug fails in mid-to-late stage trial
Denali Therapeutics' ALS drug fails in mid-to-late stage trial
Jan 6, 2025
Jan 6 (Reuters) - Denali Therapeutics ( DNLI ) said on Monday its experimental drug failed to meet the main goal of a mid-to-late stage trial involving patients with amyotrophic lateral sclerosis (ALS), a fatal neurodegenerative disease. Shares of the drug developer were down 6.6% in extended trade following the announcement. The study's main goal was to demonstrate a change...
Copyright 2023-2026 - www.financetom.com All Rights Reserved